We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more OK
Menu Search : Safety Update Information for Healthcare Professionals

You are here:

  1. Therapy Areas
  2. Oncology
  • Home
  • About Roche
  • Therapy Areas
  • Safety, Health and Wellbeing
  • Media
  • Social Value
  • Careers
  • Contact Us
banner

Safety Update Information for Healthcare Professionals (Oncology):

 

DHCP Tecentriq Atezolizumab Injection 1200MG..20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018


DHCP Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018


DHPC Tecentriq Atezolizumab Injection 1200mg20ml Important Identified risk immune related nephritis dated 30th July, 2018


DHPC Tecetriq Atezolizumab Injection 1200mg20ml Safety Update Identified risk -Immune-related myositis dated 31st January 2019

 

 

Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close

Related Links

  • Oncology Transplantation Anaemia Rheumatoid Arthritis Haemophilia Personalised Healthcare Cancer Immunotherapy
  • © 2019
  • 12.03.2019
  • Legal Statement
  • Privacy Policy

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.